LLY - Eli Lilly and Company

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $1,345.40 DETAILS

Stock News

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.

Sep 08, 2026 02:51 PM • zacks.com

Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?

IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.

Sep 08, 2026 10:59 AM • fool.com

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

Sep 08, 2026 10:30 AM • fool.com

Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits

Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.

Sep 08, 2026 10:00 AM • fool.com

2 Beaten-Down Stocks to Avoid Right Now

Don't catch a falling knife.

Sep 08, 2026 10:00 AM • fool.com

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.

Sep 08, 2026 09:08 AM • 247wallst.com

Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Sep 08, 2026 06:31 AM • zacks.com

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Sep 08, 2026 06:26 AM • zacks.com

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Sep 08, 2026 05:31 AM • zacks.com

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Sep 07, 2026 07:07 AM • zacks.com

Here's Why Eli Lilly (LLY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sep 07, 2026 06:45 AM • zacks.com

Athena Investment Management Lowers Holdings in Eli Lilly and Company $LLY

Athena Investment Management lessened its stake in Eli Lilly and Company (NYSE: LLY) by 35.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 831 shares of the company's stock after selling 450 shares during the quarter. Athena Investment Management's holdings in Eli Lilly and

Sep 07, 2026 01:32 AM • defenseworld.net

Burford Brothers Inc. Buys New Shares in Eli Lilly and Company $LLY

Burford Brothers Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE: LLY) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 890 shares of the company's stock, valued at approximately $1,068,000. A number of

Sep 07, 2026 12:21 AM • defenseworld.net

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.

Sep 06, 2026 04:51 AM • marketbeat.com

Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock

Griffin's Citadel Advisors and Druckenmiller's Duquesne Family Office bought Lilly stock in Q2. The billionaires likely capitalized on an opportunity with Lilly's shares tumbling early in the quarter.

Sep 06, 2026 12:51 AM • fool.com

Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.

Eli Lilly hasn't split its stock in nearly 30 years, but as shares trade above $1,000, the pharmaceutical company could be considering one. Considering other high-profile stock splits in recent years, count on company-specific catalysts, not the split itself, to drive further gains.

Sep 05, 2026 10:32 AM • fool.com

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Sep 05, 2026 04:30 AM • marketwatch.com

Great News for Eli Lilly Stock Investors

Eli Lilly's tirzepatide is showing potential across autoimmune diseases. The medicine could earn additional indications and attract broader insurance coverage over time.

Sep 03, 2026 10:00 AM • fool.com

Aspen sees Mounjaro Africa sales above $124 million in 2027

Aspen Pharmacare expects African sales ‌of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging demand in South Africa and planned launches in Nigeria and Kenya.

Sep 03, 2026 04:38 AM • reuters.com

Lilly's Record Stock Price Is Hiding an Even Bigger Opportunity

Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.

Sep 02, 2026 08:30 AM • 247wallst.com